Qlife Holding AB (publ) (STO:QLIFE)

Market Cap	55.50M +132.1%
Revenue (ttm)	324.00K +548.0%
Net Income	-20.56M
EPS	-1.64
Shares Out	28.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,487
Average Volume	39,040
Open	1.944
Previous Close	1.922
Day's Range	1.828 - 1.944
52-Week Range	1.205 - 5.740
Beta	0.57
RSI	46.40
Earnings Date	May 1, 2026

About Qlife Holding AB

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vitami, and D-dimer. Qlife Holding AB (publ) was incorporated in 2019 and is based in Helsingborg, Sweden.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2019
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLIFE

Financial Performance

In 2025, Qlife Holding AB's revenue was 324,000, an increase of 548.00% compared to the previous year's 50,000. Losses were -20.56 million, -63.24% less than in 2024.